NCT03771066

Bisphenol A and Muscle Insulin Sensitivity

Completed NA Last updated 8 July 2024

What this trial tests

NA trial testing bisphenol A in Insulin Sensitivity in 40 participants. Completed in 31 December 2023.

Timeline

1 January 2019

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	California Polytechnic State University-San Luis Obispo
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	40
Start date	1 January 2019
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across United States

Drugs / interventions tested

• bisphenol A
• Placebo

Conditions studied

• Insulin Sensitivity — all drugs for Insulin Sensitivity →
• Glucose Metabolism Disorders — all drugs for Glucose Metabolism Disorders →
• Microtia — all drugs for Microtia →

Sponsor

California Polytechnic State University-San Luis Obispo

Who can join

Adults 18 to 50, any sex, with Insulin Sensitivity or Glucose Metabolism Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study examine oral bisphenol A consumption on muscle insulin sensitivity and hepatic glucose suppression. Half of the participants will receive a diet plus BPA and the other half will receive a diet plus no bisphenol A.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Rationale and design of a randomized controlled trial examining oral administration of bisphenol A on hepatic glucose production and skeletal muscle insulin sensitivity in adults.
   Hagobian TA, Brunner-Gaydos H, Seal A, Schaffner A, et al · · 2020 · cited 2× · PMID 32154432 · DOI 10.1016/j.conctc.2020.100549
2. CLARITY-BPA Program in Rats: Is It Translatable to Humans?
   Hagobian T. · · 2019 · cited 2× · PMID 31286104 · DOI 10.1210/js.2019-00126